We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Melanocyte Stem Cells and UVB Responsible for Some Cancers

By LabMedica International staff writers
Posted on 01 Nov 2017
Cancer researchers working with mouse melanoma models have identified a mechanism responsible for the initiation of skin cancer through the interaction of ultraviolet light (UVB) and melanocyte stem cells.

Melanoma is one of the deadliest cancers, yet the cells of origin and mechanisms of tumor initiation have not been identified. More...
The majority of melanomas emerge from clear skin without a precursor lesion, but it is not known whether these melanomas can arise from melanocyte stem cells (MCSCs).

To clarify this point, investigators at Cornell University (Ithaca, NY, USA) employed mouse models to define the role of MCSCs as melanoma cells of origin. In particular, they evaluated the effect of the Hmga2 protein in MCSCs. This protein is encoded by the HMGA2 gene and belongs to the non-histone chromosomal high-mobility group (HMG) protein family. HMG proteins contain structural DNA-binding domains and may act as transcriptional regulating factors that function as architectural factors. The expression of HMGA2 in adult tissues is commonly associated with both malignant and benign tumor formation, as well as certain characteristic cancer-promoting mutations.

The investigators worked with mice carrying mutated MCSCs with intact HMGA2 and with another group in which HMGA2 had been deleted.

Results published in the October 12, 2017, online edition of the journal Cell Stem Cell revealed that Hmga2 (High-mobility group AT-hook 2) in the skin played a critical role in UVB-mediated melanoma formation and that abrogation of Hmga2 function in the microenvironment could suppress MCSC-originating cutaneous melanomas. The investigators concluded that melanomas originated from melanoma-competent MCSCs upon stimulation by UVB, which induced MCSC activation and translocation via an inflammation-dependent process.

“If you had mutations that were sufficient for melanoma, everything would be fine until you went out and got a sunburn,” said senior author Dr. Andrew White, assistant professor of biomedical sciences at Cornell University. “We have an actual mechanism, with Hmga2, that can be explored in the future and could be a way we can prevent melanomas from happening.”

Related Links:
Cornell University


New
Gold Member
Automatic Hematology Analyzer
CF9600
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Thyroid Test
Anti-Thyroid EIA Test
New
Gold Member
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.